Sorrento Therapeutics, Inc.

Summer may be over, but the heat is rising in the world of biopharmaceutical financings with some big private and public company financings announced just after the 2 September Labor Day holiday, the

If late-stage clinical development of antibody-drug conjugates is largely the preserve of big pharma, earlier work is being done by smaller, younger groups. An analysis of ADCs in Phase I/II trials sh

The South Korean pharma industry is beginning to feel the fallout from the prolonged national walkout by trainee doctors that began in February. Although the overall impact from the medical strike app

Sorrento Therapeutics, Inc. ’s BTK inhibitor, abivertinib, has potential to fill the vacuum in marginal zone lymphoma (MZL) that AbbVie Inc. and Johnson & Johnson left in April when they withdrew